Investor Newsletter Q1 2014
Released
Released
Announcement PDF
INVESTOR
UPDATE
MARCH 2014
Dear Shareholders,
Welcome to Invion’s first 2014 investor
newsletter. It’s already been a big year for Invion,
with the announcement of our collaboration
with 3M Drug Delivery Systems and a successful
capital raising, where new institutions have seen
the value behind Invion’s drug development
strategy and joined our register.
On 21 February, we announced that a private
placement to institutional and sophisticated
investors was oversubscribed, and raised
$5 million at 7.5 cents per share. Invion also
announced a rights issue entitlement offer
to raise $2 million, consisting of a 1-for-20
non-renounceable entitlement offer of fully
paid ordinary shares, at the same price as the
institutional placement.
The offer to eligible investors opened on 11
March and will close on 25 March. Hard copies
of the Rights Issue Information Booklet and
personalised applications were issued to
shareholders last week.
Invion will have the opportunity to target the
multi billion dollar respiratory market with three
potential drug candidates – oral INV102, inhaled
INV102 and inhaled INV104.
Invion continues to focus on progressing our
portfolio of treatments targeting inflammatory
and respiratory disease. There is significant
recent precedent with pharmaceutical
partnering deals for drugs in the lupus space,
and Invion is remains heavily focussed on
securing a partner for the INV103 (ala-Cpn10).
We look forward to keeping our investors
updated as we make additional progress
throughout the year.
Sincerely,
Dr Greg Collier
Managing Director and CEO
Our collaboration with 3M, a global leader
in pressured metered dose inhaler (PMDI)
technology, kick starts the next phase of
Invion’s strategic development and growth,
and was a catalyst for the capital raising.
Inhaled respiratory drugs may provide
advantages over other delivery methods due
to their targeted delivery, smaller doses and
fewer side effects. If Invion’s inhaled
treatments prove safe and effective in patients,
For further information on the Rights Issue Entitlement Offer, please contact the Entitlement
Offer Information Line on 1300 910 051, or contact Melanie Farris, Company Secretary
& Head of Operations via investor@inviongroup.com.
ASX:IVX
CONTENTS
Welcome: from Dr Greg Collier
News: Developing Invion’s inhaled franchise
Research: Science behind Nadolol receives
independent validation
Update: Investor relations
Invion: at a glance
STOP PRESS:
3M to Sponsor the 10th annual Asthma
& COPD Conference taking place this
April in London.
This year’s event will focus on the cutting
edge concepts driving the developments
of asthma and COPD forward.
Invion was mentioned in 3M’s press release.
For further information follow this link:
http://www.einpresswire.com/
article/192476230/3m-to-sponsor-the10th-annual-asthma-copd-conferencetaking-place-this-april-in-london
Developing Invion’s
inhaled franchise
Invion’s agreement with 3M Drug Delivery
Systems will assess the feasibility of inhaled
versions of INV102 (nadolol) and INV104
(zafirlukast), delivered using 3M’s proprietary
pressurized metered dose inhalation
(pMDI) technology.
It will also enable manufacture for toxicology,
and subsequently phase I studies, under
an Investigational New Drug application
sponsored by Invion with the US Food
and Drug Administration (FDA).
This will begin in the first half of 2014 and
progress as follows:
• Inhaled monotherapy INV102 (nadolol) as
a COPD treatment to pre-IND stage and
commencing phase I studies, during 1H 2015
• Feasibility for inhaled INV102 (nadolol)
combination therapies, targeted to treat
cystic fibrosis and asthma, during 1H 2015
• Inhaled monotherapy INV104 (zafirlukast)
as a treatment for asthma to IND stage and
commencing phase I studies, during 1H 2015
• Feasibility for inhaled INV104 (zafirlukast)
combination therapies targeted to treat
asthma, during 1H 2015.
Spectrum of airway disease and opportunities
Global market size: $34B
Exercise
Induced
Asthma
Mild
Asthma
Moderate
Asthma
Severe
Asthma
Zafirlukast
1H14
Asthma
oral program, ongoing phase II study
Smoking cessation
COPD
Smoker’s
Cough
Cystic
Fibrosis
Monotherapy + combinations
This expansion into the development of
inhaled therapies adds significant potential
to the value of Invion’s assets, and is an
= beta adrenergic inverse agonistEOP2
$1.2B
Nadolol
Monotherapy + combinations
INV102 (nadolol)
Chronic
Bronchitis
$2.4B
important step toward commercialising
our drug development pipeline. The inhaled
treatment pipeline is outlined below.
2H14
1H15
Next milestone
(calendar year)
Completion 2Q15
EOP2
inhaled monotherapy: formulation and development
commence ph III
EOP2 4Q14
pre-IND, commence ph I
Pre IND 1Q15
feasibility: inhald
monotherapy + ICS
feasibility: inhald
monotherapy + antibiotic
Asthma
= leukotriene receptor antagonist
Hear Invion MD & CEO Dr Greg Collier
discussing the inhaled respiratory
franchise and the collaboration with
3M at: brrmedia.com/event/120626
Asthma
inhaled monotherapy: formulation and development
IND, commence ph I
IND 2Q15
feasibility: inhald
combination therapies
Asthma
How does COPD differ from asthma?
Although COPD and asthma have similar characteristics such as the signs of coughing and wheezing, they are two distinct
conditions in terms of disease onset, frequency of symptoms and reversibility of airway obstruction.
Asthma
COPD
• The onset of asthma typically occurs during childhood or adolescence.
• COPD most often develops in smokers and former smokers who are in
their mid-40s.
• Exacerbations of asthma -- characterized by recurrent wheezing,
shortness of breath, chest tightness and cough -- often have identifiable
triggers such as allergens, cold air or exercise.
• With treatment, asthma patients have near-normal lung function and are
symptom-free between exacerbations.
• The first-line maintenance therapy for most patients with moderate
asthma is an inhaled corticosteroid, with the addition of a bronchodilator
if needed to control symptoms.
Reference: The American Association for Respiratory Care http://www.aarc.org/
• Exacerbations in COPD patients are commonly caused by respiratory
tract infections.
• COPD patients rarely experience a day without symptoms. Airflow
obstruction in COPD sufferers is only partially reversible with smoking
cessation and bronchodilator use.
• The reverse is true for the treatment of COPD. Bronchodilators are the
first-line maintenance treatment for COPD. Treatment with inhaled
corticosteroids is reserved only for selected patients whose COPD
is not adequately managed with bronchodilators.
Research: Science behind nadolol
receives independent validation
The American Journal of Respiratory and
Critical Care Medicine has published a letter
advocating the use of nadolol as a potentially
effective treatment for asthma and
respiratory disease (Vol. 189, No. 3, February
2014). This letter was written by Dr Raymond
Penn, Director of Pulmonary Research at the
Jane and Leonard Korman Lung Center in
Philadelphia, Pennsylvania.
Dr Penn’s response is significant in validating
the scientific principles behind Invion’s inhaled
respiratory drug franchise, and reiterates his
confidence in Professor Richard Bond’s theory
of ‘inverse agonism’. This theory explains how
nadolol, a beta blocker which is conventionally
used to treat heart diseases and headaches,
can be used inversely to treat lung disease by
stimulating the smooth muscles in the lungs
for contraction.
However following the precedent and parallel
pharmacology of beta adrenergic inverse
agonists, a subclass of beta blockers to which
INV102 belongs, as a treatment for chronic
heart failure, also once contraindicated, it is
hypothesized that longer-term dosing of INV102
may also provide a safe and effective therapy
for the treatment of asthma”, said Dr Glass.
“About one in two regular smokers dies of a
smoking related disease, losing on average
16 years of life. This is a significant global
health problem and a huge commercial space.
A therapy which can reduce or eliminate
smokers cough, a key barrier to quitting
smoking, could be life changing for patients”,
said Dr Glass.
As a world-class expert in pulmonary (lung)
medicine, Dr Glass is highly qualified to
comment on the potential value of a drug
effective at treating smokers cough. The smoking
cessation drug market was estimated at
$2.4 billion in 2012.
As Invion returns to the clinic for a series of
phase II trials for INV102, Dr Glass’ experience
and strong networks in the United States will
be an invaluable aid to the Company’s clinical
planning, design and execution.
“Tobacco is a known or probable cause of at least
25 diseases, including lung and other cancers,
heart disease, stroke, emphysema and other
chronic lung diseases, and people who smoke
have higher rates of wound infection following
surgical procedures.
For more information on The American
Journal of Respiratory and Critical Care
Medicine, and access to published articles,
please click on a link to their website here.
(http://www.atsjournals.org/journal/ajrccm)
What is inverse agonism?
• “Receptors” are found on the surface of cells and receive chemical signals
originating externally from the cell. When signals bind to a receptor they
direct a cell to a certain action. Receptors can exist as “active” or “inactive”.
•A
n agonist is a chemical that binds to an “active” receptor of a cell and
triggers a response by that cell (it causes an action).
• An antagonist blocks the action of the agonist (neutralising an action).
• An inverse agonist, by preferring and selecting the “inactive” state
of a receptor, inhibits the constitutive activity of the receptor, causing
an action opposite to that of the agonist.
Control
Vehicle S/C
Nad 28 d S/C
Control lung tissue.
Lung tissue of ‘asthmatic’ mice – epithelial cells
have been converted to mucus producing goblet
cells. No effect of alprenolol.
Lung tissue of asthmatic mice treated
with b-adrenergic inversive agonist
INV102 for 28 days: restored epithelium.
Investor Relations update
A highlight of our recent IR activities was the JP Morgan Healthcare Conference in San Francisco in January, where approximately 300 private and public
companies presented to 4,000 investors.
Invion also featured more recently in London as part of the ASX Spotlight Series which featured a number of emerging Australian companies,
particularly in the life sciences sector.
These events provided an ideal opportunity to raise Invion’s profile with both potential partners and investors. Other upcoming conferences at which
the Company will either be presenting to investors, or in professional attendance are outlined below:
April 1
Shaw Stockbroking healthcare day?
Melbourne, Australia
April 8 – 9
BIO Asia International Conference
Toyko, Japan
May 16
American Thoracic Society
San Diego, USA
June 4 – 6
Asia Biotech Invest 2014
Hong Kong
Invion at a glance
Invion is a clinical-stage life sciences company focussed on the development of treatments for major opportunities in the inflammatory diseases
market including asthma and COPD ($34B) and systemic lupus erythematosus (lupus) (to $4B).
Invion has three drug assets – INV102 (nadolol); INV104 (zafirlukast); and INV103 (ala-Cpn10) – and three FDA-regulated, phase II clinical trials,
which are currently underway in the US.
Following the announcement of a partnership with 3M Drug Delivery Systems, Invion will also be developing inhaled treatment options for INV102
and INV104, to treat a range of inflammatory respiratory diseases.
Invion has an experienced management team in Managing Director & CEO Dr Greg Collier (former ChemGenex CEO), and Executive Vice President
R&D and Chief Medical Officer, Dr Mitchell Glass (5 drugs approved with FDA and 50 INDs).
Contact details:
Dr Greg Collier
Managing Director and CEO, Invion Limited
GPO Box 1557, Brisbane, QLD 4001 Australia
P: +61 7 3295 0500
E: investor@inviongroup.com
W: www.inviongroup.com
Twitter: @InvionLimited
Linked In: linkedin.com/company/invion-limited
US Office
Suite 700, 901 Market St, Wilmington,
Delaware 19801 USA
P: +1 302 295 4855
Share your feedback
Discover